10 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2041
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jul 2041 · High confidence
Also notable
Ends May 2041 · Medium confidence
Anti-Abeta Antibodies
US 11,434,283
A family of 13 related applications built on the 2022 grant. Protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
US 12,247,056
A family of 7 related applications built on the 2025 grant. Too new for citation comparison; protection runs to 2041.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Oct 2 to 23, 2027 · next Oct 2
Recent changes
- Sep 16Assignment recorded on 1 record: Prothena Biosciences Inc. to Othair Prothena Limited Recorded Sep 16, 2026, executed Mar 13, 2023. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76504, frame 819.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Anti-Abeta Antibodies | 5 in force | to Jul 2041 |
| Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | 4 in force | to May 2041 |
| Multiepitope Vaccine for the Treatment of Alzheimer's Disease | 1 in force | to Feb 2043 |
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,945,849 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | In force | Medium confidence | |
| US 11,952,406 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | In force | Medium confidence | |
| US 11,965,005 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | In force | Medium confidence | |
| US 12,247,056 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | In force | Medium confidence | |
| US 11,434,283 | Anti-Abeta Antibodies In force · High confidence | In force | High confidence | |
| US 11,434,284 | Anti-Abeta Antibodies In force · High confidence | In force | High confidence | |
| US 11,434,285 | Anti-Abeta Antibodies In force · High confidence | In force | High confidence | |
| US 11,440,953 | Anti-Abeta Antibodies In force · High confidence | In force | High confidence | |
| US 12,435,129 | Anti-Abeta Antibodies held by Prothena Biosciences Limited and Othair Prothena Limited In force · High confidence | In force | High confidence | |
| US 12,661,392 | Multiepitope Vaccine for the Treatment of Alzheimer's Disease In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 10 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.